



**SERES**  
THERAPEUTICS™

## Seres Therapeutics to Present at Goldman Sachs 38th Annual Global Healthcare Conference

June 6, 2017

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 6, 2017-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will participate in a webcast discussion at the Goldman Sachs 38<sup>th</sup> Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 13 at 4 p.m. PT.

Live audio webcast will be available under the Investors and Media section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

### About Seres Therapeutics

Seres Therapeutics is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. The company is planning to initiate the ECOSPOR III clinical study with its lead program, SER-109, in patients with multiply recurrent *C. difficile* infection. Seres' second clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis. Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary *C. difficile* infection. For more information, please visit [www.serestherapeutics.com](http://www.serestherapeutics.com). Follow us on Twitter [@SeresTx](https://twitter.com/SeresTx).



View source version on businesswire.com: <http://www.businesswire.com/news/home/20170606006175/en/>

Source: Seres Therapeutics, Inc.

### IR and PR Contact:

Seres Therapeutics  
Carlo Tanzi, Ph.D., 617-203-3467  
Head of Investor Relations and Corporate Communications  
[Ctanzi@serestherapeutics.com](mailto:Ctanzi@serestherapeutics.com)